Related Experiment Videos
Sotalol
1Division of Cardiology, University of Utah Medical Center, Salt Lake City 84132.
Journal of Cardiovascular Electrophysiology
|February 1, 1993
Summary
Sotalol, a dual-action antiarrhythmic drug, effectively suppresses most cardiac arrhythmias. Further trials are needed to compare its safety and efficacy against other treatments.
Area of Science:
- Pharmacology
- Cardiology
Background:
- Sotalol exhibits noncardioselective beta-adrenergic antagonism and Class III electrophysiologic action.
- This dual profile provides significant antiarrhythmic properties.
Purpose of the Study:
- To review the pharmacologic profile, efficacy, and safety of sotalol as an antiarrhythmic agent.
- To highlight the need for further randomized controlled trials.
Main Methods:
- Review of sotalol's pharmacokinetic properties (bioavailability, elimination half-life).
- Analysis of its efficacy in suppressing various cardiac arrhythmias.
- Examination of potential adverse effects and risk mitigation strategies.
Main Results:
- Sotalol is highly bioavailable orally and eliminated unchanged in urine with a 15-17 hour half-life.
- Effective in suppressing most arrhythmias, except those linked to prolonged ventricular repolarization.
- Adverse effects include those of beta-blockade and QT prolongation.
Conclusions:
- Sotalol possesses unique antiarrhythmic properties due to its dual mechanism.
- Further research is essential to establish its comparative safety and efficacy in unselected patient populations.
- Risk of torsade de pointes can be minimized by dose limitation and avoiding hypokalemia.